Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 0.60 |
| ▸ | TYK2 | P29597 | 18/20 | 0.60 |
| ▸ | JAK1 | P23458 | 18/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 17/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283220 | 0.91 | JAK1 (0.53) | JAK3TYK2JAK1CYP3A4JAK2 | |
| SCHEMBL2223737 | 0.89 | JAK1 (0.62) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2226063 | 0.88 | JAK1 (0.54) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2279030 | 0.88 | JAK1 (0.62) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2223333 | 0.87 | JAK1 (0.62) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2273239 | 0.86 | JAK1 (0.58) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2276343 | 0.86 | JAK1 (0.54) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2273829 | 0.85 | JAK3 (0.58) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2276045 | 0.84 | JAK2 (0.52) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL2278830 | 0.84 | JAK1 (0.54) | JAK3TYK2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |